(Q38093322)

28 August 2017

title

Tuberculosis biomarkers discovery: developments, needs, and challenges (English)

1 reference

28 August 2017

0 references

0 references

8

1 reference

28 August 2017

Markus Maeurer

6

0 references

Stewart Cole

3

object named as

Stewart Cole

1 reference

28 August 2017

Robert S Wallis

1

1 reference

28 August 2017

Peter Kim

2

1 reference

28 August 2017

Debra Hanna

4

1 reference

28 August 2017

Bruno B Andrade

5

1 reference

28 August 2017

Marco Schito

7

1 reference

28 August 2017

publication date

24 March 2013

1 reference

Lancet Infectious Diseases

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

362-372

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Sustainable tuberculosis drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Predicting the outcome of therapy for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

(18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

The scent of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Volatile biomarkers of pulmonary tuberculosis in the breath.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Interferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Dynamic Antigen-specific T-Cell Responses after Point-Source Exposure toMycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

A whole blood bactericidal assay for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Whole Blood Bactericidal Activity during Treatment of Pulmonary Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Neopterin, beta 2-microglobulin, and acute phase proteins in HIV-1-seropositive and -seronegative Zambian patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Serum C-reactive protein and detection of tuberculosis in persons co-infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Predicting deterioration of treated tuberculosis by corticosteroid reserve and C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Evaluation of Human Antimycobacterial Immunity Using Recombinant Reporter Mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Novel human in vitro system for evaluating antimycobacterial vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

A single dose of vitamin D enhances immunity to mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Identification of probable early-onset biomarkers for tuberculosis disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Apoptosis and T Cell Hyporesponsiveness in Pulmonary Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Comparative miRNA expression profiles in individuals with latent and active tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Immunological biomarkers of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Biomarkers for tuberculosis disease activity, cure, and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Biomarkers for tuberculosis disease activity, cure, and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Early bactericidal activity of new drug regimens for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Rapid detection of Mycobacterium tuberculosis biomarkers in a sandwich immunoassay format using a waveguide-based optical biosensor.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Biogenesis of the mycobacterial cell wall and the site of action of ethambutol

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Human gene expression profiles of susceptibility and resistance in tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Host biomarkers of clinical relevance in tuberculosis: review of gene and protein expression studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Increased levels of circulating interleukin-18 in patients with advanced tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Subclinical tuberculosis: a new entity?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Antigens of Mycobacterium tuberculosis recognized by antibodies during incipient, subclinical tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Use of antibodies in lymphocyte secretions for detection of subclinical tuberculosis infection in asymptomatic contacts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Dynamic changes in biomarker profiles associated with clinical and subclinical tuberculosis in a high transmission setting: a four-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Proteome-scale antibody responses and outcome of Mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Cell-mediated immune responses in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Tim-3-expressing CD4+ and CD8+ T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

SOCS3 promotes interleukin-17 expression of human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Antimicrobial activity of mucosal-associated invariant T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Human mucosal associated invariant T cells detect bacterially infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Tuberculosis vaccines: a strategic blueprint for the next decade

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

A genome-wide identification analysis of small regulatory RNAs in Mycobacterium tuberculosis by RNA-Seq and conservation analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Peripheral T cell cytokine responses for diagnosis of active tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Specific cytokine patterns of pulmonary tuberculosis in Central Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

Proteomic analysis identifies highly antigenic proteins in exosomes from M. tuberculosis-infected and culture filtrate protein-treated macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970034-3

7 January 2021

10.1016/S1473-3099(13)70034-3

Identifiers

DOI

1 reference

28 August 2017

1 reference